Cardiac hypertrophy: Sorting out the circuitry

Current Opinion in Genetics and Development

Volumn 9, Issue 3, 1999, Pages 267-274

  McKinsey, Timothy A ^a   Olson, Eric N ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATASE; TRANSCRIPTION FACTOR;

CELL SIZE; HEART DILATATION; HEART FAILURE; HEART MUSCLE CELL; HEART OUTPUT; HEART VENTRICLE HYPERTROPHY; HUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033152768     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(99)80040-9     Document Type: Article

References (54)

1. Sugden PH, Clerk A: Cellular mechanisms of cardiac hypertrophy. J Mol Med 1998, 76:725-746.
2. Rockman HA, Koch WJ, Lefkowitz RJ: Cardiac function in genetically engineered mice with altered adrenergic receptor signaling. Am J Physiol 1997, 272:H1553-H1559.
3. Bristow MR: Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997, 80:26L-40L.
4. 1B- adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 1994, 91:10109-10113.
5. Zamazaki T, Yazaki Y: Is there major involvement of the renin-angiotensin system in cardiac hypertrophy? Circ Res 1997, 81:639-642.
6. Hein L, Stevens ME, Barsh GS, Pratt RE, Kobilka BK, Dzau VJ: Overexpression of angiotensin AT1 receptor transgene in mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc Natl Acad Sci USA 1997, 94:6391-6396.
7. Sugaya T, Nishimatsu S, Tanimoto K, Takimoto E, Yamagishi T, Fukuta M, Fukamizu A, Murakami K: Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 1995, 270:18719-18722.
8. Harada K, Komuro I, Shiojima I, Hayashi D, Kudoh S, Mizuno T, Kijima K, Matsubara H, Sugaya T, Murakami K, Yazaki Y: Pressure overload induces cardiac hypertrophy in angiotensin II type 1a knockout mice. Circulation 1997, 97:1952-1959.
9. D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, Dorn GW: Transgenic Gq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci USA 1997, 94:8121-8126.
10. Mende U, Kagen A, Cohen A, Aramburu J, Schoen FJ, Neer EJ: Transient cardiac expression of consitutively active Gq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci USA 1998, 95:13893-13898.
11. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ: Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998, 280:574-577. This study shows that targeted expression of a carboxy-terminal peptide of the alpha subunit of Gq to the heart reduces cardiac hypertrophy in response to pressure overload. The study demonstrates the importance of Gq signaling in pressure overload hypertrophy and suggests that inhibitors of Gq may be useful in the treatment of heart failure.
12. Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ, Ross J, Lefkowitz RJ, Koch WJ: Expression of β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci USA 1998, 95:7000-7005. Expression of a β-ARK inhibitor in the heart of transgenic mice is here shown to restore new cardiac function and prevent chamber enlargement in response to null mutation of the muscle LIM domain protein (MLP). These results suggest an important role for β-adrenergic receptor/G protein coupling in heart failure and suggest possible therapeutic approaches involving β-ARK inhibition.
13. Koch WJ, Rockman HA, Samama P, Hamilton R, Bond RA, Milano CA, Lefkowitz RJ: Cardiac function in mice overexpressing the β- adrenergic receptor kinase or a β-ARK inhibitor. Science 1995, 268:1350-1353.
14. Arber S, Hunter JJ, Ross J, Hongo M, Sansig G, Borg J, Perriard JC, Chien KR, Caroni P: MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 1997, 88:393-403.
15. 1-adrenergic receptor and ras activation and is associated with in vitro and in vivo hypertrophy. J Biol Chem 1997, 272:14057-14061.
16. Hunter JJ, Tanaka N, Rockman HA, Ross J, Chien KR: Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 1995, 270:23173-23178.
17. Abdellatif M, Packer SE, Michael LH, Zhang D, Charng MJ, Schneider MD: A ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: Implications for cardiac hypertrophy. Mol Cell Biol 1998, 18:6729-6736.
18. Thorburn J, Xu S, Thorburn A: MAP kinase- and Rho-dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells. EMBO J 1997, 16:1888-1900.
19. 2-terminal kinase in ventricular muscle cells. J Biol Chem 1998, 273:5423-5426.
20. Choukroun G, Hajjar R, Kyriakis JM, Bonventre JV, Rosenzweig A, Force T: Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. J Clin Invest 1998, 102:1311-1320.
21. Nemoto S, Sheng Z, Lin A: Opposing effects of jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy. Mol Cell Biol 1998, 18:3518-3526.
22. Zechner D, Thuerauf DJ, Hanford DS, McDonough PM, Glembotski CC: A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J Cell Biol 1997, 139:115-127.
23. Clerk A, Michael A, Sugden PH: Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: A role in cardiac hypertrophy? J Cell Biol 1998, 142:523-535.
24. Zechner D, Craig R, Hanford DS, McDonough PM, Sabbadini RA, Glembotski CC: MKK6 activates myocardial cell NF-κB and inhibits apoptosis in a p38 mitogen-activated protein kinase-dependent manner. J Biol Chem 1998, 273:8232-8239.
25. Wang Y, Huang S, Sah VP, Ross J, Brown JH, Han J, Chien KR: Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998, 273:2161-2168.
26. Sheng Z, Knowlton K, Chen J, Hosijima M, Brown JH, Chien KR: Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. J Biol Chem 1997, 272:5783-5791.
27. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, Chien KR, Brown JH, Dorn GW: Enhanced Gq signaling: A common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 1998, 95:10140-10145.
28. Hasegawa K, Lee SJ, Jobe SM, Markham BE, Kitsis RN: Cis-acting sequences that mediate induction of the -myosin heavy chain gene during left ventricular hypertrophy due to aortic constriction. Circulation 1997, 96:3943-3953.
29. Herzig TC, Jobe SM, Aoki H, Molkentin JD, Cowley AW, Izumo S, Markham BE: Angiotensin II type 1a receptor gene expression in the heart: AP-1 and GATA4 mediate the response to pressure overload. Proc Natl Acad Sci USA 1997, 94:7543-7548.
30. Molkentin JD, Olson EN: GATA4: A novel transcriptional regulator of cardiac hypertrophy? Circulation 1997, 96:3833-3835.
31. Molkentin JD, Lu J, Antos CL, Markham B, Richardson J, Robbins J, Grant S, Olson EN: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228. The authors of this paper demonstrate that activated calcineurin and activated NFAT3 are sufficient to activate cardiac hypertrophy in vivo. The results show that the calcineurin inhibitor, cyclosporin A, blocks Ang II and PE-mediated cardiac hypertrophy in vitro. These studies uncover a novel hypertrophic signaling pathway connecting the membrane to the nucleus.
32. Rao A, Luo C, Hogan PG: Transcription factors of the NFAT family: Regulation and function. Annu Rev Immunol 1997, 15:707-747.
33. Schreiber SL, Crabtree GR: The mechanism of action of cyclosporin A and FK506. Immunol Today 1992, 13:136-142.
34. Chin ER, Olson EN, Richardson J, Yang Q, Humphries C, Shelton JM, Wu H, Zhu W, Bassel-Duby R, Williams RS: A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev 1998, 12:2509.
35. Fentzke RC, Korcarz CE, Lang RM, Lin H, Leiden JM: Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. J Clin Invest 1998, 101:2415-2426.
36. 2+ flux. Cell 1995, 83:463-472.
37. Dolmetsch RE, Lewis RS, Goodnow CC, Healy JI: Differential activation of transcription factors induced by Ca2+ response amplitude and duration. Nature 1997, 386:855-858. This paper demonstrates that calcineurin activation and the resulting dephosphorylation of NFAT occurs specifically in response to a low, sustained calcium plateau, whereas activation of NF-κB by c-Jun amino-terminal Kinase (JNK) occurs in response to a large transient calcium rise. These results demonstrate how intracellular calcium-regulated signaling systems can distinguish between different types of calcium signals and thereby activate specific transcriptional programs in the nucleus. The results are especially relevant to understanding the role of calcium in cardiac hypertrophy.
38. 2+, strong cross-bridge binding, and protein phosphorylation. J Biol Chem 1996, 271:11611-11614.
39. Sussman MA, Lim HW, Cambon N, Taigen T, Olson EN, Robbins J, Colbert MC, Wieczorek DF, Molkentin JD: Prevention of cardiac cardiac hypertrophy by calcineurin inhibition. Science 1998, 281:1690-1693. The authors report that cardiomyopathy in response to misexpression of sarcomeric proteins in the heart can be prevented by systemic cyclosporin A administration. These results suggest that at least certain forms of hypertrophy arising from altered sarcomeric functions may involve calcineurin activation. The study also demonstrates that pressure overload hypertrophy in rats can be prevented by cyclosporin A, further implicating calcineurin in this process.
40. Colbert MC, Hall DG, Kimball TR, Witt SA, Lorenz JN, Kirby ML, Hewett TE, Klevitsky R, Robbins J: Cardiac compartment-specific overexpression of a modified retinoic acid receptor produces dilated cardiomyopathy and congestive heart failure in transgenic mice. J Clin Invest 1997, 100:1958-1968.
41. Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, Olson EN, Vatner SF: Cyclosporine attenuates pressure overload hypertrophy in mice, while enhancing susceptibility to decompensation and heart failure. Circ Res 1999, 84:735-740.
42. Luo Z, Shyu K-G, Gualberto A, Walsh K: Calcineurin inhibitors and cardiac hypertrophy. Nat Med 1998, 4:1092-1093.
43. Zhang W, Kowal RC, Rusnak F, Sikkink RA, Olson EN, Victor RG: Failure of calcineurin inhibitors to prevent pressure- overload left ventricular hypertrophy in rats. Circ Res 1999, 84:722-728.
44. Muller JG, Nemoto S, Laser M, Carabello BA, Menick DR, Molkentin JD: Calcineurin inhibition and cardiac hypertrophy. Science 1998, 282:1007a.
45. Bowman JC, Steinberg SF, Jiang T, Greenan DL, Fishman GI, Buttrick PM: Expression of protein kinase C in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 1997, 100:2189-2195.
46. Wakasaki H, Koya D, Schoen F, Jirousek MR, Ways DK, Hoit BD, Walsh RA, King GL: Targeted overexpression of protein kinase C 2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 1997, 94: 9320-9325.
47. 2+-sensitive isoforms in the failing human heart. Circulation 1999, 99:384-391.
48. Pennica D, King KL, Shaw KJ, Rullamas E, Luoh SM, Decabonne WC, Knutzon DS, Yen R, Chien KR, Baker JB, Wood WI: Expression cloning of cardiotrophin-1, a cytokine that induces cardiac hypertrophy. Proc Natl Acad Sci USA 1995, 92:1142-1146.
49. Kodama H, Fukuda K, Pan J, Makino S, Baba A, Hori S, Ogawa S: Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 1997, 81:656-663.
50. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL: Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997, 95:1247-1252.
51. Bozkurt B, Kribbs SB, Clubb FJ, Michael LH, Didenko VV, Hornsby DJ, Seta Y, Oral H, Spinale FG, Mann DL: Pathophysiologically relevant concentrations of tumor necrosis factor alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998, 97:1382-1391.
52. Bryant D, Becker L, Richardson J, Shelton JM, Franco F, Peshock R, Thompson M, Giroir B: Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998, 97:1375-1381.
53. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM: Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. J Biol Chem 1998, 273:24037-24043.
54. 2+/calmodulin-dependent protein kinase II regulates atrial natriuretic factor gene expression in ventricular myocytes. J Biol Chem 1997, 272:31203-31208.